Source: Eli Lilly & Company
Period: 05/15/2017 – 5/14/2019
Title: Evaluation of Olaratumab (IMC-3G3) an Anti-PDGFR Antibody, with or without Concomitant Chemotherapy Against Pediatric Cancer Xenografts with High Level PDGFR Expression
Project Goal: Evaluate olaratumab (anti-PDGFRalpha antibody) with or without standard care of chemotherapy (1 agent) or LSC3214996 against KT-12 and KT-14 rhabdoid xenograft models.
Role: Co-Investigator
Since 2004, UT Health San Antonio, Greehey Children’s Cancer Research Institute’s (Greehey CCRI) mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. Our mission consists of three key areas — research, clinical, and education.
Stay connected with the Greehey CCRI on Facebook, Twitter, LinkedIn, and Instagram.